15.1% average weight loss
Average body weight fell 15.1% after 1 year on oral semaglutide.*
91% of people
Adults lost at least 5% of their starting weight after 72 weeks with tirzepatide injections.*
88.9% of men
Men showed improved hair growth in photos after 24 weeks of using topical minoxidil 5% with finasteride 0.1%.*
Sources and study details
* Rodriguez et al., JAMA Internal Medicine (2024): observational study of 18,386 matched adults receiving Ozempic (semaglutide) or Mounjaro (tirzepatide); 52% had type 2 diabetes. Figures describe Ozempic users still on treatment, not men-specific results. Actual doses were not verified; discontinuation ended follow-up for 52.5% of semaglutide users. Each milestone is a separately published estimate, including statistical imputation for missing weights, not a prorated annual result. Percentages represent cumulative loss from starting weight and should not be added together. Ozempic use for weight management is off-label. Results concern approved Ozempic injections, not LIV’s compounded formula, which is not FDA-approved; individual results vary.
* Original source. Sheikh et al. (2015), J Clin Exp Dermatol Res 6:253, Results and Figure 2. Randomized open-label multicenter trial of MorrF lipid solution (5% minoxidil plus 0.1% finasteride), 1 mL twice daily for 24 weeks in adult men with androgenetic alopecia. 88.9% had slightly, moderately or greatly increased growth by photographic assessment; 60.0% with minoxidil alone. This is the studied topical formulation, not any prescribed oral combination or every compounded vehicle/strength. Patient assessment scores were also collected; not recast as response percentages. This study followed men using minoxidil and finasteride together on the scalp.
** For 94.1%: Hu et al., 2015. The combination arm used oral finasteride 1 mg daily plus topical minoxidil 5%; 152 of 160 Chinese men assigned to this arm were evaluated at 12 months. This was a two-product regimen, not a test of LIV's compounded topical blend. Original study.
